Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minnelide in Relapsed/Refractory AML
NCT03347994Phase 1Withdrawn
- Start
- Apr 2018
- Primary completion
- Apr 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 1, open-label trial of minnelide in acute myeloid leukemia (AML) (4 arms). Primary endpoints: Rate of Toxicity in Study Participants up to 13 months, Maximum Tolerated Dose and 1 more. Planned start Apr 2018; status: withdrawn.
02
Drugs
minnelide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03347994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03347994.